BioSpace News Archive

Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has filed a provisional patent application in the United States covering the recently communicated mRNA molecules found in pre-clinical trials to be effective at destroying cancer cells grown in culture.

Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced positive top-line Phase 2 results from the FILLMORE monotherapy trial for AMT-101 in patients with chronic pouchitis, an orphan indication with significant unmet medical need and no current FDA-approved therapies.

Xalud Therapeutics today announced the appointment of Amy Chappell, M.D., as an independent strategic advisor.

Aeterna Zentaris Inc. today announced that results from pre-clinical studies of Aeterna’s AIM Biologicals for the potential treatment of Parkinson’s Disease (“PD”) were accepted for presentation at IMMUNOLOGY2022.

BrickBio presented an invited poster at the annual meeting of the American Association of Cancer Research (AACR) Conference highlighting some of the results from its multi-year effort to develop the most efficacious therapeutic sites, inaccessible to other technologies, that the company incorporated into its Site Select Panel™.

AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that 400 patients have now been enrolled in the main trial population in the pivotal Phase 3 REVIVAL study.

Lineage Cell Therapeutics, Inc. today announced a new cell therapy development program: photoreceptor neural cell (PNC) transplants for the treatment of vision loss due to photoreceptor dysfunction or damage.

Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ:GRFS), today announced the completion of the acquisition of 100% of the share capital of Tiancheng (Germany) Pharmaceutical Holdings AG, a German company that holds 89.88% of the ordinary shares and 1.08% of the preferred shares of Biotest AG, a European healthcare company specialized in innovative hematology and clinical immunology.

Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the Redeye Orphan Drugs Conference on April 27, 2022.

Hologic, Inc. (Nasdaq: HOLX) announced today that the American Society of Clinical Oncology (ASCO) has published an update which expands the utility of Breast Cancer Index™ (BCI) within its Clinical Practice Guideline: “Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer.”